EUROPEAN DRUG REPORT 2016

02/10/2016 Press 1891 Views
EUROPEAN DRUG REPORT 2016

Information on drug use, markets and related problems, European policies on drugs and practices: these are the trends that the European Drug Report 2016 has collected, with the collaboration of the European Commission, Europol, the European Centre for Disease Prevention and Control (EMCDDA), and the European Medicine Agency.

This year’s analysis once more highlights how Europe increasingly faces a more complex drug problem, in which stimulants, new psychoactive substances, misused medicines and problematic cannabis use all play a greater part”, Laura d’Arrigo, chair of EMCDDA Management Board and Alexis Goosdeel, director of EMCDDA, wrote in the preface. They also stated that “some of the problems of the past remain with us — even if the challenges they are now presenting for both policy and practice are changing. Europe’s opioids problem remains a central issue in the 2016 analysis, reflecting the significant impact these drugs still have on mortality and morbidity. We see now an increasingly complex relationship between use of heroin and synthetic opioids, accompanied by a worrying increase in overall estimates of opioid-related deaths”. Whereas among the new challenges for drug policy, Internet’s role both as a communication medium and a source of drug supply.

The European Drug Report 2016 can be downloaded here

About author

Related articles

?>